期刊文献+

非抗菌活性红霉素衍生物研究进展 被引量:2

Recent developments in erythromycin derivatives with non-antibacterial activity
下载PDF
导出
摘要 目的综述非抗菌活性红霉素衍生物的研究进展。方法依据国内外近期公开发表的40篇文献,对非抗菌活性红霉素衍生物的研究进展进行分类、归纳与总结。结果长期以来,红霉素及其衍生物作为抗菌药物被广泛使用。在临床实践中人们发现,该类化合物还具有一些新的生物活性,例如促进消化道运动、抗炎/免疫调节、抗寄生虫、抗肿瘤、拮抗黄体生成素释放激素、以及抑制磷酸二酯酶-3等活性。为提高新活性降低其抗菌作用,已经设计、合成了多种类型的新结构红霉素衍生物。结论利用红霉素衍生物的新活性研制、开发新药已经成为研究热点。 Objective To review the recent developments in erythromycin derivatives with non-antibacterial activity. Methods According to forty of the published papers and patents, the recent developments in erythro- mycin derivatives with non-antibacterial activity were classified and summarized. Results Erythromycin and its derivatives had been extensively used in the treatment of bacterial infections for decades, however, indica- ted that they also have some new bioactivities. Such as motiline-like activity, anti-inflammatory and/or im- munomodulatory activity, antiparasitic activity, antitumor activity, luteinizing hormone-releasing hormone in- hibitory activity, and phosphodiesterase-3 inhibitory activity. In order to maximize these new activities of e- rythromycin while attenuate its antibacterial activity, several series of novel erythromycin derivatives had been designed and synthesized. Conclusions The research and development of erythromycin derivatives with new bioactivities have gradually become an important part of erythromycin derivatives research, which pos- sess a good prospect.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2015年第8期660-668,共9页 Journal of Shenyang Pharmaceutical University
基金 国家自然科学基金资助项目(30973614)
关键词 红霉素 衍生物 非抗菌活性 构效关系 erythromycin derivative non-antibacterial activity structure-activity relationship
  • 相关文献

参考文献40

  • 1TSUZUKI K,SUNAZUKA T,MARUI S,et al.Motilides,macrolides with gastrointestinal motor stimulating activity.I.O-substituted and tertiary Nsubstituted derivatives of 8,9-anhydroerythromycin A 6,9-hemiacetal[J].Chem Pharm Bull,1989,37(10):2687-2700.
  • 2OMURA S,TSUZUKI K,SUNAZUKA T,et al.Macrolides with gastrointestinal motor stimulating activity[J].J Med Chem,1987,30(11):1941-1943.
  • 3LARTEY P A,NELLANS H N,FAGHIH R,et al.Synthesis of 4″-deoxy motilides:identification of a potent and orally active prokinetic drug candidate[J].J Med Chem,1995,38(10):1793-1798.
  • 4LIU Yao-quan,CARRERAS C,MYLES D C,et al.Motilide compounds:US,2006127252[P].2006-11-30.
  • 5SHAW S J,CHEN Yue,ZHENG Hao,et al.Structure-activity relationships of 9-substituted-9-dihydroerythromycin-based motilin agonists:optimizing for potency and safety[J].J Med Chem,2009,52(21):6851-6859.
  • 6LIU Yao-quan,LI Yong,CHEN Yue,et al.9-Dihydroerythromycins as non-antibiotic motilin receptor agonists[J].Bioorg Med Chem Lett,2010,20(19):5658-5661.
  • 7LIU Yao-quan,LI Yong,MYLES D C,et al.9-Dihydroerythromycin ethers as motilin agonists-developing structure-activity relationships for potency and safety[J].Bioorg Med Chem,2010,18(21):7651-7658.
  • 8LIU Yao-quan,CARRERAS C W,CLAYPOOL M,et al.The role of the 4″-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series[J].Bioorg Med Chem Lett,2011,21(12):3712-3714.
  • 9PUKHALSKY A L,SHMARINA G V,KAPRANOV N I,et al.Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease[J].Mediators Inflamm,2004,13(2):111-117.
  • 10SCALIONE F,ROSSONI G.Comparative anti-infllammatory effects of roxithromycin,azithromycin and clarithromycin[J].J Antimicrob Chemother,1998,41(Suppl.B):47-50.

同被引文献41

  • 1丁成慧.硝苯地平的临床应用进展[J].现代医药卫生,2007,23(14):2121-2122. 被引量:6
  • 2韦芝群.小剂量红霉素对新生儿胃肠动力障碍的影响[J].华夏医学,2007,20(4):771-772. 被引量:5
  • 3Liang J H, An K, Lv W, et al. Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime I 1,12-cyclic carbonate ketolides [J]. EurJMedChem, 2013, 59(1): 54-63.
  • 4Sanger G J, Wang Y, Hobson A, et al. Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists[J]. Br J Pharmacol, 2013,170(7): 1323- 1332.
  • 5Yan M, Ma X D, Dong R Q, et al. Synthesis and antibacterial activity of 4"-O-(trans-fl-arylacrylamido) carbamoyl azithromycin analogs [J]. Eur d Med Chem, 2015,103: 506-515.
  • 6Zhang L, Chai X Y, Wang B G, et aL Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents [J]. Bioorg Med Chem Lett, 2013, 23(18): 5057-5060.
  • 7Blondeau J M, Shebelski S D, Hesje C K. Killing of Streptococcus pneumoniae by azitbromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimuminhibitory concen- trations and mutant prevention concentrations [J]. lnt J Antimicrob Agents, 2015, 45(6): 594-599.
  • 8Park B D, Min Y H. Inducible expression of erm(B) by the ketolides telithromycin and cethromycin[J]. Int J A ntimierob Agents, 2015, 46(2): 226-227.
  • 9Takashi N, Tatsuro Y, Yukitoshi N, et al. 9-Oxirne-3-ketolides: modification at the C-I 1,12-diol moiety and antibacterial activities against key respiratory pathogens[J]. Bioorg Med Chem, 2005, 13(21): 6054-6063.
  • 10Phan L T, Or Y S, Ma Z, et al..6-O-Carbamate ketolide derives: WO, 00/75156A1 [P]. 2000-12-14.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部